- Report
- June 2022
- 86 Pages
North America
From €1374EUR$1,500USD£1,170GBP
- Report
- January 2024
- 168 Pages
Global
€4575EUR$4,995USD£3,895GBP
- Report
- January 2024
- 39 Pages
United States
- Report
- January 2024
- 84 Pages
United States
- Report
- May 2023
- 92 Pages
Middle East, Africa, Global Middle East, Africa, Global
From €3500EUR$4,094USD£3,084GBP
- Report
- July 2022
- 176 Pages
Global
From €2216EUR$2,419USD£1,886GBP
€3165EUR$3,456USD£2,695GBP
- Report
- July 2022
- 280 Pages
Global
From €2216EUR$2,419USD£1,886GBP
€3165EUR$3,456USD£2,695GBP
- Book
- April 2018
- 248 Pages
- Book
- October 2020
- 288 Pages
- Book
- October 2019
- 632 Pages
- Book
- April 2018
- 776 Pages
United States
- Book
- January 2016
- 368 Pages
- Book
- May 2014
- 616 Pages
- Book
- May 2014
- 256 Pages
- Book
- May 2013
- 400 Pages
- Book
- March 2010
- 512 Pages

Prostate cancer is a type of cancer that affects the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. It is the most common cancer in men in the United States, and the second most common cause of cancer death in men. Prostate cancer is typically treated with surgery, radiation therapy, hormone therapy, chemotherapy, or a combination of these treatments.
The prostate cancer market within the oncology space is a rapidly growing segment, driven by the increasing prevalence of the disease and the development of new treatments. The market is expected to benefit from the introduction of novel therapies, such as immunotherapies and targeted therapies, which are expected to improve the prognosis of patients. Additionally, the increasing focus on early diagnosis and the development of new diagnostic tools are expected to drive the market growth.
Some of the key players in the prostate cancer market include AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi. Show Less Read more